Antero (AR) was upgraded to hold from underperform at Jefferies. $27 price target. Management has addressed key concerns, Jefferies said.
Groupon (GRPN) was upgraded to overweight from neutral at Piper Jaffray. $6 price target. Customer ramp should outperform expectations, Piper said.
Humana (HUM) was upgraded to buy at Jefferies. $210 price target. The risk/reward is attractive, even if the Aetna deal breaks, Jefferies said.
Monster Beverage (MNST) was downgraded to market perform from outperform at Wells Fargo. The company has limited earnings upside potential, Wells said.
Merck (MRK) was downgraded to market perform from outperform at BMO Capital. The valuation is less attractive, based on a $62 price target, BMO said.
PacWest (PACW) was downgraded to neutral at DA Davidson. The valuation is less attractive, based on a $45 price target, Davidson said.
Parexel (PRXL) was downgraded to market perform from outperform at William Blair. The surprise CFO departure is concerning on multiple fronts, William Blair said.
QEP (QEP) was upgraded to outperform at BMO Capital. The valuation is more attractive, based on a $24 price target, BMO said.
Regal (RGC) was downgraded to sector perform from outperform at RBC Capital. $23 price target. The valuation is less attractive, with shares up 15% over the past month, RBC said.